Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Ocera Therapeutics, Inc. OCRX, a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that 6 abstracts involving the company's drug candidate OCR-002, ornithine phenylacetate, have been accepted for presentation at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held from November 13-17, 2015, in San Francisco, CA. These abstracts include new data supporting the continued evaluation of OCR-002 as a new liver disease therapeutic.